Division of Thoracic Surgery, Department of Surgery, CETOC - CHUM Endoscopic Tracheobronchial and Oesophageal Center, University of Montréal, Montréal, Québec, Canada; Division of Pulmonary and Critical Care, UCSF - Fresno Medical Education Program, Advanced Interventional Thoracic, Endoscopy/Interventional Pulmonology, University of California San Francisco (UCSF), Fresno, California.
Division of Thoracic Surgery, Department of Surgery, CETOC - CHUM Endoscopic Tracheobronchial and Oesophageal Center, University of Montréal, Montréal, Québec, Canada.
Semin Thorac Cardiovasc Surg. 2020 Spring;32(1):162-168. doi: 10.1053/j.semtcvs.2019.07.007. Epub 2019 Jul 17.
Positron emission tomography (PET) with computed tomography (CT) is routinely utilized to investigate lymph node (LN) metastases in non-small-cell lung cancer. However, it is less sensitive in normal-sized LNs. This study was performed in order to define the prevalence of mediastinal LN metastases discovered on combined endosonography by endobronchial ultrasound (EBUS) and endoscopic ultrasound (EUS) fine needle aspiration in patients with a radiologically normal mediastinum. This study consists of a retrospective, single-institution, tertiary care referral center review of a prospectively maintained database. Patients were identified from a cohort between January 2009 and December 2014. One hundred and sixty-one patients with biopsy-proven, non-small-cell lung cancer were identified in whom both the preendosonography CT and PET-CT were negative for mediastinal LN metastases. Combined endosonography (EBUS + EUS-FNA) was performed in all patients. Z test was used for statistical analysis. A P value of <0.05 was considered statistically significant. A total of 161 consecutive patients were included. Patients were staged if they had central tumor, tumor size >3 cm, N1 lymph node involvement on PET-CT/CT, or if there was low SUV (<2.5) in the primary tumor. A total of 416 lymph nodes were biopsied in the 161 patients using combined endosonography; 147 with EBUS and 269 with EUS. Mean and median number of lymph nodes biopsied per patient using combined EBUS/EUS was 2.5 and 3, respectively (mean and median EBUS: 0.91 and 2.5; mean and median EUS 1.6 and 3). Endosonographic staging upstaged 13% of patients with radiologically normal lymph nodes in the mediastinum, hilum, lobar, and sublobar regions (confidence interval 8.22-19.20). Twenty-one out of 161 patients (13%) with radiologically normal mediastinum were positive on combined EBUS/EUS staging. Out of 21 patients upstaged on endosonography, 15 (71%) had tumor size >3 cm. Six (28%) had occult N1 disease. Thirteen (61%) had occult N2 disease and 2 (9%) had adrenal involvement. None of the upstaged patients had N1 LN involvement on PET-CT or CT scan. Combined endosonographic lymph node staging should be considered in the pretreatment staging of high-risk patients with non-small-cell lung cancer in the presence of radiologically normal mediastinal lymph nodes due to the significant rate of radiologically occult lymph node metastases.
正电子发射断层扫描(PET)与计算机断层扫描(CT)联合应用于非小细胞肺癌的淋巴结(LN)转移的常规检查。然而,对于正常大小的 LN,其敏感性较低。本研究旨在明确在影像学正常的纵隔中,经支气管超声内镜(EBUS)和内镜超声(EUS)细针抽吸术联合进行的纵隔内 LN 转移的发现率。本研究为回顾性、单机构、三级医疗转诊中心研究,对前瞻性维护的数据库进行了回顾。从 2009 年 1 月至 2014 年 12 月的一个队列中确定了患者。在经活检证实患有非小细胞肺癌且经超声前 CT 和 PET-CT 均未发现纵隔 LN 转移的 161 例患者中识别出。对所有患者均进行了联合内镜超声检查(EBUS+EUS-FNA)。采用 Z 检验进行统计学分析。P 值<0.05 被认为具有统计学意义。共纳入 161 例连续患者。如果患者有中央肿瘤、肿瘤大小>3cm、PET-CT/CT 上有 N1 淋巴结受累或原发肿瘤的 SUV 值较低(<2.5),则对其进行分期。在 161 例患者中使用联合内镜超声共对 416 个淋巴结进行了活检;147 个经 EBUS 活检,269 个经 EUS 活检。使用联合 EBUS/EUS 活检的每位患者的平均和中位数淋巴结活检数分别为 2.5 和 3(平均和中位数 EBUS:0.91 和 2.5;平均和中位数 EUS:1.6 和 3)。在影像学正常的纵隔、肺门、肺叶和亚肺叶区域,内镜超声分期使 13%的患者出现纵隔淋巴结分期升高(置信区间为 8.22%至 19.20%)。在 161 例影像学正常的纵隔患者中,21 例(13%)经联合 EBUS/EUS 分期呈阳性。在 21 例经内镜超声分期升高的患者中,15 例(71%)肿瘤大小>3cm。6 例(28%)存在隐匿性 N1 疾病。13 例(61%)存在隐匿性 N2 疾病,2 例(9%)存在肾上腺累及。在 PET-CT 或 CT 扫描上无任何分期升高的患者存在 N1 LN 受累。由于影像学隐匿性淋巴结转移的发生率较高,对于影像学正常的纵隔淋巴结的高危非小细胞肺癌患者,在治疗前应考虑进行联合内镜超声淋巴结分期。